Answers are grounded in this paper and cite their sources.
Preclinical xenograft study reveals that BDNF-TrkB signaling coordinates lymphovascular metastasis in head and neck cancer models, highlighting a rationale for targeted therapy.
impact of CAF pathophysiology in the tumor microenvironment in animal xenograft models revealed that HNSCC cell lines in combination with CAFs promoted tumor growth and increased incidence of lymphovascular metastasis as compared to injection of tumor cells or CAF cells alone. Using pharmacological and genetic alterations, we mechanistically demonstrate the critical importance of BDNF-TrkB signaling in the tumor microenvironment. These investigations further support the rationale for BDNF/TRKB targeted therapy against in the treatment of HNSCC.
No takes yet. Share an insight, caveat, or question.
Jiffar et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: